The global psoriasis treatment market is projected to expand at a compound annual growth rate (CAGR) of 8.5% by 2026. Key factors fueling this growth include the rising prevalence of psoriasis, increasing demand for psoriasis medications in emerging markets, greater approval of new biologic drugs for treatment, ongoing research advancements, a robust pipeline of innovative therapies, and the growing adoption of combination treatments for managing the condition.
Download Sample PDF: https://meditechinsights.com/psoriasis-treatment-market/request-sample/
Psoriasis is a chronic, multifactorial inflammatory disorder characterized by the accelerated growth of keratinocytes in the epidermis, resulting in an increased turnover rate of skin cells. It manifests in various forms, including plaque, flexural, guttate, nail, and psoriatic arthritis. The condition typically affects areas such as the elbows, knees, scalp, lower back, intergluteal clefts, and the glans penis. In up to 30% of cases, joint involvement is also observed.
The treatment of psoriasis depends on the extent of the affected body areas, the presence of joint involvement, and the severity of the plaques. Currently, treatment options include topical therapies, systemic medications, and phototherapy, with combination approaches often employed to achieve optimal results.
Surge in Biologic Drug Use for Plaque Psoriasis Drives Market Growth
The advent of biologic drugs has revolutionized the treatment landscape for psoriasis. Biologics are derived from living organisms and specifically target immune system components responsible for the overactivity seen in psoriasis. These drugs work by blocking immune cells or proteins that trigger the disease, effectively preventing the immune system from going into overdrive. Recently, several biologic treatments have been approved by the U.S. Food and Drug Administration (FDA) for plaque psoriasis, including:
- May 2022: Dermavant Sciences received FDA approval for VTAMA (tapinarof) cream 1%, a steroid-free topical treatment for plaque psoriasis in adults. This approval marked VTAMA as the first cream in its class to be FDA-approved.
- August 2021: Novartis secured FDA approval for Cosentyx® (secukinumab) for treating moderate-to-severe pediatric plaque psoriasis in China.
- February 2021: Amgen submitted a supplemental New Drug Application (sNDA) to the FDA for Otezla (apremilast), aimed at treating adults with mild-to-moderate plaque psoriasis.
Interleukin (IL) Inhibitors’ Increasing Role in Psoriasis Treatment
Interleukin inhibitors, which block the action of interleukins—key proteins involved in inflammation—have become a cornerstone of psoriasis treatment. Previously, treatment relied on non-biologic options like topical corticosteroids, vitamin D analogues, and keratolytics. However, the introduction of biologics targeting specific immune pathways, such as tumor necrosis factor (TNF) inhibitors and IL inhibitors, has greatly improved treatment outcomes.
IL inhibitors have gained preference due to their higher safety profiles, more targeted actions, faster onset of effects, and more durable responses. Notable recent approvals include:
- January 2022: SKYRIZI® (risankizumab-rzaa), an IL-23 inhibitor, received FDA approval for treating active psoriatic arthritis (PsA) in adults.
- December 2021: Cosentyx® (secukinumab) was approved by the FDA for treating active enthesitis-related arthritis (ERA) and psoriatic arthritis in patients as young as two years old.
Download Sample PDF: https://meditechinsights.com/psoriasis-treatment-market/request-sample/
Rise of Combination Therapies in Psoriasis Treatment
Combination therapy, which pairs two or more drugs, is becoming the standard treatment for psoriasis, particularly in patients who don’t respond adequately to single-agent therapies. This approach can enhance therapeutic outcomes while minimizing safety concerns and reducing the risk of cumulative toxicity. Commonly used combinations include topical steroids combined with vitamin D analogues or other topical treatments, as well as steroid plus systemic therapies. The growing use of combination treatments is expected to drive continued market expansion in the coming years.
Key Challenges in the Psoriasis Treatment Market
Despite advances in treatment, several challenges remain in the psoriasis treatment market. High treatment costs, the lifelong nature of the condition, and the limited coverage by health insurance schemes are significant barriers. Additionally, the lack of standardized diagnostic tools, complex regulatory processes for new drug approvals, and the potential for adverse side effects with existing medications further hinder market growth.
North America: Dominant in the Psoriasis Treatment Market
North America holds a substantial share of the psoriasis treatment market, driven by high rates of plaque psoriasis and psoriatic arthritis, as well as a growing volume of biologic drug prescriptions. There is also increased awareness about psoriasis diagnosis and treatment in the region. Meanwhile, the Asia-Pacific region is expected to see significant growth due to rising awareness, increased demand for biologics, and an uptick in research and development for new treatments.
Competitive Landscape in the Psoriasis Treatment Market
Key players in the global psoriasis treatment market include Eli Lilly & Company, Pfizer Inc., Janssen Global Services, Celgene Corporation, Takeda Pharmaceutical Company, Novartis, Amgen, Biogen, AbbVie, AstraZeneca, and several others. These companies are adopting various strategies, including partnerships, acquisitions, and the launch of new products, to gain a competitive edge.
Focus on New Biological Products Drives Market Innovation
Several pharmaceutical companies are intensifying efforts to develop new biologic therapies for psoriasis. For example:
- July 2022: Arcutis Biotherapeutics received FDA approval for ZORYVE (roflumilast) cream 0.3%, a new topical treatment for plaque psoriasis.
- December 2021: AbbVie’s RINVOQ® (upadacitinib) was approved by the FDA for adults with active psoriatic arthritis who did not respond adequately to TNF blockers.
- October 2021: Sun Pharmaceutical Industries launched ILUMYA injections for moderate-to-severe plaque psoriasis in Canada.
Browse Report: https://meditechinsights.com/psoriasis-treatment-market/
About Medi-Tech Insights;
Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.
Contact:
Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
